Mitochondrial DNA copy-number variation and pancreatic cancer risk in the prospective EPIC cohort

Manuel Gentiluomo, Verena A. Katzke, Rudolf Kaaks, Anne Tjønneland, Gianluca Severi, Vittorio Perduca, Marie Christine Boutron-Ruault, Elisabete Weiderpass, Pietro Ferrari, Theron Johnson, Matthias B. Schulze, Manuela Bergmann, Antonia Trichopoulou, Anna Karakatsani, Carlo La Vecchia, Domenico Palli, Sara Grioni, Salvatore Panico, Rosario Tumino, Carlotta SacerdoteBas Bueno-De-Mesquita, Roel Vermeulen, Torkjel M. Sandanger, J. Ramón Quirós, Miguel Rodriguez-Barranco, Pilar Amiano, Sandra Colorado-Yohar, Eva Ardanaz, Malin Sund, Kay Tee Khaw, Nicholas J. Wareham, Julie A. Schmidt, Paula Jakszyn, Luca Morelli, Federico Canzian, Daniele Campa

Producció científica: Article en revista indexadaArticleAvaluat per experts

16 Cites (Scopus)


Background: Mitochondrial DNA (mtDNA) copy number in peripheral blood has been found to be associated with risk of developing several cancers. However, data on pancreatic ductal adenocarcinoma (PDAC) are very limited. Methods: To further our knowledge on this topic, we measured relative mtDNA copy number by a quantitative real-time PCR assay in peripheral leukocyte samples of 476 PDAC cases and 357 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Results: We observed lower mtDNA copy number with advancing age (P = 6.54 x 10-5) and with a high body mass index (BMI) level (P = 0.004) and no association with sex, smoking behavior, and alcohol consumption. We found an association between increased mtDNA copy number and decreased risk of developing PDAC with an odds ratios (OR) of 0.35 [95% confidence interval (CI), 0.16-0.79; P = 0.01] when comparing the fifth quintile with the first using an unconditional logistic regression and an OR of 0.19 (95% CI, 0.07-0.52; P = 0.001) with a conditional analysis. Analyses stratified by BMI showed an association between high mtDNA copy number and decreased risk in the stratum of normal weight, consistent with the main analyses. Conclusions: Our results suggest a protective effect of a higher number of mitochondria, measured in peripheral blood leukocytes, on PDAC risk. Impact: Our findings highlight the importance of understanding the mitochondrial biology in pancreatic cancer.

Idioma originalAnglès
Pàgines (de-a)681-686
Nombre de pàgines6
RevistaCancer Epidemiology Biomarkers and Prevention
Estat de la publicacióPublicada - 2020


Navegar pels temes de recerca de 'Mitochondrial DNA copy-number variation and pancreatic cancer risk in the prospective EPIC cohort'. Junts formen un fingerprint únic.

Com citar-ho